Stereotaxis to Report Third Quarter 2024 Financial Results on November 11, 2024
Stereotaxis (NYSE: STXS), a pioneer in surgical robotics for minimally invasive endovascular intervention, announced it will release its 2024 third quarter financial results on November 11, 2024, after U.S. market close. The company will host a conference call and webcast at 4:30 p.m. ET to discuss results and corporate developments. Stereotaxis technology has been used to treat over 150,000 patients globally across the United States, Europe, Asia, and other regions.
Stereotaxis (NYSE: STXS), un pioniere nella robotica chirurgica per interventi endovascolari minimamente invasivi, ha annunciato che pubblicherà i suoi risultati finanziari del terzo trimestre 2024 l'11 novembre 2024, dopo la chiusura del mercato negli Stati Uniti. L'azienda organizzerà una chiamata e un webcast alle 16:30 ET per discutere i risultati e gli sviluppi aziendali. La tecnologia di Stereotaxis è stata utilizzata per trattare oltre 150.000 pazienti in tutto il mondo, negli Stati Uniti, in Europa, in Asia e in altre regioni.
Stereotaxis (NYSE: STXS), un pionero en robótica quirúrgica para intervenciones endovasculares mínimamente invasivas, anunció que publicará sus resultados financieros del tercer trimestre de 2024 el 11 de noviembre de 2024, después del cierre del mercado estadounidense. La empresa llevará a cabo una llamada y un webcast a las 4:30 p.m. ET para discutir los resultados y los desarrollos corporativos. La tecnología de Stereotaxis ha sido utilizada para tratar a más de 150,000 pacientes en todo el mundo, incluyendo Estados Unidos, Europa, Asia y otras regiones.
Stereotaxis (NYSE: STXS)는 최소 침습 혈관 내 시술을 위한 외과 로봇의 선구자로, 2024년 11월 11일 미국 시장 마감 후 2024년 3분기 재무 결과를 발표할 것이라고 발표했습니다. 회사는 오후 4시 30분(ET)에 결과 및 회사 개발 사항을 논의하기 위한 컨퍼런스 콜 및 웹캐스트를 개최할 예정입니다. Stereotaxis 기술은 미국, 유럽, 아시아 및 기타 지역에서 전 세계적으로 150,000명 이상의 환자를 치료하는 데 사용되었습니다.
Stereotaxis (NYSE: STXS), un pionnier dans la robotique chirurgicale pour les interventions endovasculaires minimales, a annoncé qu'il publiera ses résultats financiers pour le troisième trimestre 2024 le 11 novembre 2024, après la clôture du marché américain. L'entreprise organisera une conférence téléphonique et un webinaire à 16h30 ET pour discuter des résultats et des développements de l'entreprise. La technologie de Stereotaxis a été utilisée pour traiter plus de 150 000 patients dans le monde, aux États-Unis, en Europe, en Asie, et dans d'autres régions.
Stereotaxis (NYSE: STXS), ein Pionier in der chirurgischen Robotik für minimal-invasive endovaskuläre Eingriffe, gab bekannt, dass die finanziellen Ergebnisse des dritten Quartals 2024 am 11. November 2024 nach Börsenschluss in den USA veröffentlicht werden. Das Unternehmen wird um 16:30 Uhr ET eine Telefonkonferenz und einen Webcast abhalten, um die Ergebnisse und die Unternehmensentwicklungen zu besprechen. Die Technologie von Stereotaxis wurde weltweit zur Behandlung von über 150.000 Patienten in den USA, Europa, Asien und anderen Regionen eingesetzt.
- None.
- None.
ST. LOUIS, Oct. 23, 2024 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today announced that it will release financial results for its 2024 third quarter on Monday, November 11, 2024 at the close of the U.S. financial markets. The Company will host a conference call and webcast at 4:30 p.m. ET that day to discuss the Company’s results and corporate developments.
| What: | Stereotaxis third quarter 2024 financial results conference call | |
| When: | Monday, November 11, 2024, at 4:30 p.m. ET (1:30 p.m. PT) | |
| Dial In Number: | To access the live call, dial 800-715-9871 (US and Canada) or 1-646-307-1963 (International) and give the participant pass code 7792742. | |
| Webcast: | To access the live and replay webcast, please visit the investor relations section of Stereotaxis’ website at http://ir.stereotaxis.com/. | |
| Call Replay: | A phone replay of the call will be available for one month beginning approximately four hours following the end of the call. To request access for a replay of the conference call, please click here. | |
About Stereotaxis
Stereotaxis (NYSE: STXS) is a pioneer and global leader in innovative surgical robotics for minimally invasive endovascular intervention. Its mission is the discovery, development and delivery of robotic systems, instruments, and information solutions for the interventional laboratory. These innovations help physicians provide unsurpassed patient care with robotic precision and safety, expand access to minimally invasive therapy, and enhance the productivity, connectivity, and intelligence in the operating room. Stereotaxis technology has been used to treat over 150,000 patients across the United States, Europe, Asia, and elsewhere. For more information, please visit www.stereotaxis.com.
Investor Contacts:
David L. Fischel
Chairman and Chief Executive Officer
Kimberly Peery
Chief Financial Officer
314-678-6100
Investors@Stereotaxis.com
FAQ
When will Stereotaxis (STXS) release Q3 2024 earnings?
How can I access Stereotaxis (STXS) Q3 2024 earnings call?
How many patients have been treated with Stereotaxis (STXS) technology?
